Weighted Average Number of Shares Outstanding, Diluted of Akebia Therapeutics, Inc. from 31 Mar 2017 to 31 Dec 2025

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
Akebia Therapeutics, Inc. quarterly and annual Weighted Average Number of Shares Outstanding, Diluted in shares history and change rate from 31 Mar 2017 to 31 Dec 2025.
  • Akebia Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending 31 Dec 2025 was 257,157,782, a 22% increase year-over-year.
  • Akebia Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2025 was 257,157,782, a 22% increase from 2024.
  • Akebia Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2024 was 210,946,658, a 13% increase from 2023.
  • Akebia Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 187,465,448, a 2.6% increase from 2022.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Change (%)

Akebia Therapeutics, Inc. Quarterly Weighted Average Number of Shares Outstanding, Diluted (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 257,157,782 +46,211,124 +22% 01 Oct 2025 31 Dec 2025 10-K 26 Feb 2026 2025 FY
Q3 2025 274,372,722 +64,024,263 +30% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 271,104,020 +61,398,623 +29% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 241,602,853 +36,647,702 +18% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 210,946,658 +23,481,210 +13% 01 Oct 2024 31 Dec 2024 10-K 26 Feb 2026 2025 FY
Q3 2024 210,348,459 +22,042,109 +12% 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025 2025 Q3
Q2 2024 209,705,397 +22,887,966 +12% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 204,955,151 +20,186,168 +11% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 187,465,448 +4,682,768 +2.6% 01 Oct 2023 31 Dec 2023 10-K 26 Feb 2026 2025 FY
Q3 2023 188,306,350 +4,423,904 +2.4% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 186,817,431 -3,557,886 -1.9% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 184,768,983 +5,169,938 +2.9% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 182,782,680 +16,832,985 +10% 01 Oct 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
Q3 2022 183,882,446 +10,100,295 +5.8% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 190,375,317 +29,045,327 +18% 01 Apr 2022 30 Jun 2022 10-Q 28 Aug 2023 2023 Q2
Q1 2022 179,599,045 +25,778,236 +17% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023 2023 Q1
Q4 2021 165,949,695 01 Oct 2021 31 Dec 2021 10-K/A 28 Aug 2023 2022 FY
Q3 2021 173,782,151 +30,467,422 +21% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 161,329,990 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 153,820,809 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q3 2020 143,314,729 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q4 2017 49,719,548 01 Oct 2017 31 Dec 2017 10-K 26 Mar 2019 2018 FY
Q3 2017 46,938,618 01 Jul 2017 30 Sep 2017 10-K 26 Mar 2019 2018 FY
Q2 2017 40,819,957 01 Apr 2017 30 Jun 2017 10-K 26 Mar 2019 2018 FY
Q1 2017 38,759,221 01 Jan 2017 31 Mar 2017 10-K 26 Mar 2019 2018 FY

Akebia Therapeutics, Inc. Annual Weighted Average Number of Shares Outstanding, Diluted (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 257,157,782 +46,211,124 +22% 01 Jan 2025 31 Dec 2025 10-K 26 Feb 2026 2025 FY
2024 210,946,658 +23,481,210 +13% 01 Jan 2024 31 Dec 2024 10-K 26 Feb 2026 2025 FY
2023 187,465,448 +4,682,768 +2.6% 01 Jan 2023 31 Dec 2023 10-K 26 Feb 2026 2025 FY
2022 182,782,680 +16,832,985 +10% 01 Jan 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
2021 165,949,695 +27,486,543 +20% 01 Jan 2021 31 Dec 2021 10-K/A 28 Aug 2023 2022 FY
2020 138,463,152 +20,067,233 +17% 01 Jan 2020 31 Dec 2020 10-K/A 28 Aug 2023 2022 FY
2019 118,395,919 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.